Menu

Press releases

25.09.2018

MaxiVAX starts Phase 2 study in Switzerland of innovative cancer vaccine in patients with Head & Neck cancer

·  Company winner of 2017 CTI Swiss Medtech Award

·  US FDA accepted IND in 2018

MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, announced today the start of an open label Phase 2 study to evaluate its MVX-ONCO-1 product in 40-45 patients with Head & Neck cancer. The study is being conducted across different sites in Switzerland in collaboration with SAKK, the Swiss Group for Clinical Cancer Research. All enrolled patients will have a confirmed diagnosis of Head and Neck Squamous Carcinoma (HNSCC), stage III/IV in recurrent or metastatic stage and will have failed standard therapy. The primary endpoint is overall survival at 26 weeks.

PDF: English Français

17.07.2018

MaxiVAX appoints T. Scott Johnson, M.D., as new Chairman

Geneva, Switzerland – 14 December, 2017 – MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, today announces the appointment of T. Scott Johnson, M.D., as Chairman, following his joining of the Board of Directors in December 2017. Dr Johnson takes over as Chairman from Dr Bernard Mach, co-founder of MaxiVAX, who remains on the Board. Dr Johnson was a Founder of The Medicines Company where he is currently Chief Medical Advisor and Vice President of Business Development. He is also a Founder and General Partner of JSB Partners, L.P., providing specialized investment banking and advisory services to biotechnology and pharmaceutical companies.

PDF: English Français

MaxiVAX announces that US FDA accepts Investigational New Drug Application

Geneva, Switzerland, 17 July 2018 - MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to conduct clinical trials in the US with its product MVX-ONCO-1.

Dimitrios Goundis, PhD, Chief Executive Officer, commented: “The FDA’s acceptance of our IND is a significant milestone for MaxiVAX. This decision validates the product attributes of MVX-ONCO-1, the promise of the preclinical and clinical data, and the quality of our production & control systems. Above all it is testament to the ingenuity and expertise of our team who are determined to make this significant potential cancer therapy available to patients as soon as possible.”

PDF: English Français

14.12.2017

MaxiVAX appoints Scott Johnson as Board Director

Geneva, Switzerland – 14 December, 2017 – MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, today announces the appointment of T. Scott Johnson, M.D., as a Board Director. Dr Johnson was a Founder of The Medicines Company where he is currently Chief Medical Advisor and Vice President of Business Development. He is also a Founder and General Partner of JSB Partners, L.P., providing specialized investment banking and advisory services to biotechnology and pharmaceutical companies.

PDF: English Français Deutsch

MaxiVAX appoints Antonio Perez as Chief Medical Officer

Geneva, Switzerland – 14 December, 2017 – MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, today announces the appointment of Antonio Perez MD Ph.D., as its Chief Medical Officer. He joins the company after holding senior medical positions at Novartis, Biogen Idec, Basilea, Almirall and Esteve. He has also been a medical advisor to many companies across Europe and the US.

PDF: English Français Deutsch

13.06.2017

MaxiVAX wins 2017 CTI Swiss Medtech Award

The 2017 CTI Swiss Medtech Award, presented at the Swiss Medtech Day on 13 June, has gone to the biotech company MaxiVAX. MaxiVAX and the Geneva University Hospitals received the CHF 15,000 prize for developing a new vaccine designed to help the immune system in cancer patients fight their own tumor cells. The award was presented by Federal Councillor Johann N. Schneider-Ammann before around 600 guests in the Kursaal, Bern.

Press release in English, French, German, Italian

Download the poster.

21.10.2016

Dr. Nicolas Mach wins grant from Swiss Cancer League

Press Release: Grant of CHF 240,000 awarded to Dr Nicolas Mach to evaluate the MaxiVAX cancer vaccine in patients with Head & Neck cancer. PDF

Communiqué de presse : Une bourse de recherche de CHF 240,000 attribuée au Dr. Nicolas Mach pour évaluer le vaccin anticancéreux de MaxiVAX chez les patients atteints du cancer de la tête et du cou. PDF

31.05.2016

Dr. Nicolas Mach wins award

Press Release: Grant of CHF 300,000 awarded to evaluate MaxiVAX cancer vaccine in Phase II study in Switzerland PDF

Communiqué de presse : Le vaccin anticancéreux de MaxiVAX reçoit un prix de CHF 300'000 pour son évaluation lors d'une étude de phase II en Suisse PDF

Pressemitteilung: Schweiz: MaxiVAX erhält CHF 300ΚΌ000 für Phase-II-Studie mit Krebs-Impfprodukt PDF

07.04.2016

MaxiVAX announces promising results from its phase 1 anti-cancer clinical trial

Press Release: MaxiVAX announces promising results from its phase 1 anti-cancer clinical trial PDF

Communiqué de presse : MaxiVAX annonce les résultats prometteurs de son étude clinique de phase I d'un vaccin anticancéreux PDF

Pressemitteilung: MaxiVAX gibt vielversprechende Ergebnisse einer klinischen Phase-I-Studie mit seinem Krebs-Impfprodukt bekannt PDF

03.02.2016

MaxiVAX appoints Dimitrios Goundis as Chief Executive Officer

Press Release: MaxiVAX appoints Dimitrios Goundis as Chief Executive Officer PDF

Communiqué de presse : MaxiVAX engage Dimitrios Goundis en tant que directeur général PDF

Pressemitteilung: MaxiVAX verpflichtet Dimitrios Goundis als CEO PDF

13.11.2014

Swiss biotech starts breakthrough anti-cancer clinical trial based on active immunotherapy

Press Release: Swiss biotech starts breakthrough anti-cancer clinical trial based on active immunotherapy PDF

Communiqué de presse: Une entreprise suisse de biotechnologie lance des essais cliniques portant sur une immunothérapie cellulaire anti-tumorale innovante PDF

Pressemitteilung: Schweizer Biotech-Unternehmen startet bahnbrechende klinische Antikrebs-Studie zu aktiver Immuntherapie PDF